Anzeige
Mehr »
Login
Samstag, 22.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Neues Allzeithoch: Sensationelle Goldfunde! - könnte das der nächste Multi-Bagger sein?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HG69 | ISIN: GB00B0LCW083 | Ticker-Symbol: H5P
Tradegate
21.02.25
08:00 Uhr
27,800 Euro
-0,200
-0,71 %
1-Jahres-Chart
HIKMA PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
HIKMA PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
27,80028,00021.02.
27,80028,00021.02.

Aktuelle News zur HIKMA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
HIKMA PHARMACEUTICALS Aktie jetzt für 0€ handeln
10.02.Hikma Pharmaceuticals to release annual results on February 264
10.02.Hikma Pharmaceutical - Notice of Results4
14.01.Hikma Partners with Emergent for the Sale of KLOXXADO in the U.S. & Canada7
14.01.EBS obtains rights to Hikma's Kloxxado naloxone spray7
14.01.Hikma Pharma Inks Exclusive Commercial Deal With Emergent BioSolutions For KLOXXADO Nasal Spray 8 Mg329LONDON (dpa-AFX) - Hikma Pharmaceuticals plc (HIK, HIK.L) announced Tuesday that it has entered an exclusive commercial partnership with Emergent BioSolutions for the sale of KLOXXADO naloxone...
► Artikel lesen
14.01.Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals147Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose emergency...
► Artikel lesen
23.12.24Hikma Pharmaceutical - Director/PDMR Shareholding2
10.12.24Broker tips: British Land, BAE Systems, Hikma, Unite, Londonmetric27
10.12.24RBC upgrades Hikma Pharmaceuticals to 'outperform'4
10.12.24LONDON BROKER RATINGS: RBC raises Hikma; JPMorgan cuts Schroders6
07.11.24Hikma Pharmaceutical - Outcome of Audit Tender Process1
07.11.24Hikma Pharmaceuticals reiterates full-year guidance amid strong growth4
07.11.24Hikma reiterates outlook on strong trading2
07.11.24Hikma Pharma Expects Revenue Growth Between 6% And 8% For FY24270LONDON (dpa-AFX) - U.K.-headquartered Hikma Pharmaceuticals PLC (HIK) on Thursday said that it remains on track to deliver another strong performance for fiscal 2024, in line with the current...
► Artikel lesen
07.11.24Hikma Pharmaceutical - Trading Statement4
24.10.24Hikma engages shareholders over buyback waiver4
24.10.24Hikma Pharmaceutical - 2024 Annual General Meeting Update Statement1
24.09.24Hikma Pharmaceutical - Director/PDMR Shareholding3
10.09.24Hikma Pharmaceuticals completes acquisition of Xellia's FDF business3
10.09.24Hikma Pharmaceutical - Hikma completes Xellia acquisition1
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1